Biogen's Fampyra Gains Conditional Approval In Europe
This article was originally published in The Pink Sheet Daily
Biogen must prove additional drug benefits in further study to gain full approval.
You may also be interested in...
CHMP Positive On Trajenta, Vectibix, Votubia And Eurartesim, But Negative On Bronchitol, Luveniq And Glybera
Europe's scientific advisory panel recommends Boehringer Ingelheim's Trajenta and Novartis's Votubia for approval, and clears new indications for Amgen's Vectibix.
The European Medicines Agency has recommended an impressive number of drugs for approval, including Merck & Co's hepatitis C therapy, Victrelis, Theravance's Vibativ and Amgen's Xgeva.
Regulators still want to see how GlaxoSmithKline's pazopanib compares with Pfizer's sunitinib